Targeted inhibition of IL-6 signaling is clinically used for treatment of rheumatoid arthritis and other autoinflammatory diseases (Tocilizumab), and has shown promising results in preclinical studies and clinical trials in various cancers [6,7,8,9]. Here, IL6 is linked to cancer.